We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-22.69%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$116M
AUM Growth
+$3.75M
Cap. Flow
+$28.9M
Cap. Flow %
24.95%
Top 10 Hldgs %
40.13%
Holding
97
New
21
Increased
22
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$5.4M
2
DERM
Dermira, Inc.
DERM
+$4.22M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$3.03M
4
NVAX icon
Novavax
NVAX
+$2.97M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$2.83M

Top Sells

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.93M
2
CYTR
CytRx Corp
CYTR
+$1.54M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$725K
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$596K
5
LOXO
Loxo Oncology, Inc
LOXO
+$476K

Sector Composition

Rank Sector Weight
1 Healthcare 73.46%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYAD
26
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$1.32M 1.14%
30,000
– –
LDRH
27
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
$1.28M 1.11%
+50,300
New +$1.05M
SPNC
28
DELISTED
Spectranetics Corp
SPNC
$1.16M 1%
79,812
– –
NVDQ
29
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.13M 0.97%
101,841
– –
DSCI
30
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.1M 0.95%
353,718
– –
ARDX icon
31
Ardelyx
ARDX
$1.24B
$1.09M 0.94%
+140,265
New +$1.38M
LOXO
32
DELISTED
Loxo Oncology, Inc
LOXO
$1.07M 0.92%
39,000
-22,737
-37% -$476K
JNJ icon
33
Johnson & Johnson
JNJ
$640B
$1.02M 0.88%
9,400
– –
MGNX icon
34
MacroGenics
MGNX
$233M
$1.02M 0.88%
54,200
+30,200
+126% +$575K
ASND icon
35
Ascendis Pharma A/S
ASND
$16.5B
$988K 0.85%
53,241
– –
LPCN icon
36
Lipocine
LPCN
$17.1M
$972K 0.84%
5,631
+2,690
+91% +$459K
MNOV icon
37
MediciNova
MNOV
$63.5M
$918K 0.79%
+125,000
New +$619K
WINT
38
DELISTED
Windtree Therapeutics Inc
WINT
$891K 0.77%
533,358
-1
-0% -$2
SGYP
39
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$813K 0.7%
294,563
– –
FOMX
40
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$774K 0.67%
118,671
+57,901
+95% +$373K
ALDX icon
41
Aldeyra Therapeutics
ALDX
$97.1M
$738K 0.64%
+176,232
New +$847K
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
$734K 0.63%
79,400
+10,000
+14% +$100K
ADVM
43
DELISTED
Adverum Biotechnologies
ADVM
$727K 0.63%
14,060
– –
ADAP
44
DELISTED
Adaptimmune Therapeutics
ADAP
$716K 0.62%
88,100
+40,000
+83% +$327K
ADMS
45
DELISTED
Adamas Pharmaceuticals
ADMS
$687K 0.59%
+47,500
New +$800K
CDNA icon
46
CareDx
CDNA
$1.83B
$675K 0.58%
136,047
– –
TBRA
47
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$666K 0.57%
81,402
-78,951
-49% -$596K
EPIX
48
DELISTED
ESSA Pharma
EPIX
$662K 0.57%
10,125
-1,300
-11% -$84.8K
DRNA
49
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$646K 0.56%
120,600
– –
CYNA
50
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$646K 0.56%
52,941
+6,312
+14% +$84.5K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, DAFNA Capital Management held 97 positions worth $116M, up 3.3% from $112M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

DAFNA Capital Management deployed $28.9M of net new capital in Q1 2016, opening 21 new positions and adding to 22 existing holdings. Its largest new stake was Dermira, Inc.: 171,881 shares worth $3.55M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 77% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Tobira Therapeutics, Inc. Common Stock, an estimated $596K trimmed.

  • DAFNA Capital Management's largest Q1 2016 buy was Dermira, Inc.: 171,881 shares worth $3.55M.
  • DAFNA Capital Management added most to VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2016, an estimated $5.4M increase.
  • DAFNA Capital Management's biggest Q1 2016 reduction was Tobira Therapeutics, Inc. Common Stock, cutting an estimated $596K.
  • DAFNA Capital Management fully exited CTI BioPharma Corp. (DE) Common Stock in Q1 2016, selling an estimated $3.93M.
  • DAFNA Capital Management's ten largest holdings make up 40% of its $116M portfolio in Q1 2016.
  • DAFNA Capital Management opened 21 new positions and closed 4 in Q1 2016.
  • DAFNA Capital Management's portfolio value rose 3.3% quarter-over-quarter to $116M.

Based on DAFNA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.